Polares Medical Raises $50M to Propel Novel Mitral Valve Implant Toward Global Trials
Polares Medical has closed a $50 million Series C financing round, fueling the next phase of clinical development for its innovative mitral valve implant, MRace. The funds are earmarked to advance ongoing trials across the United States, Europe, and Australia for patients suffering from mitral regurgitation (MR).
The investment round, which was oversubscribed, was led by DC Global Ventures and Lumination Partners, with participation from existing backers and a new, undisclosed investor.
MRace represents a distinct approach in the crowded field of transcatheter mitral interventions. Unlike dominant edge-to-edge repair systems, it works by replacing the valve's dysfunctional posterior leaflet—one of two critical flaps that prevent blood from leaking backward into the heart's left atrium. Severe MR, if untreated, can lead to heart failure, stroke, and fatal arrhythmias. A growing elderly population is driving prevalence, with recent studies estimating moderate-to-severe MR affects nearly 1% of adults globally.
"This isn't just an iteration; it's a foundational shift," said Polares CEO Jacques Essinger. "By focusing on leaflet replacement, we're opening a new chapter that could address the significant anatomical variability that challenges current repair techniques."
That variability is a key hurdle for widely adopted therapies like Abbott's MitraClip. While transformative, such devices can be less optimal for certain valve geometries. Polares claims MRace's design may offer a more universally applicable solution, particularly for complex cases of secondary MR, where the valve itself is normal but rendered leaky by underlying heart muscle disease.
The mitral valve device market is poised for expansion, with one analysis projecting the transcatheter valve sector in Europe's top five economies to reach $7.3 billion by 2033. Polares is not alone in seeking to diversify treatment options; competitor Cardiac Dimensions recently secured $53 million to advance its own alternative repair system.
Expert Reactions
Dr. Anya Sharma, Interventional Cardiologist at MetroHeart Institute: "The data from the early feasibility studies has been promising. A dedicated leaflet replacement strategy could fill a genuine gap for patients who aren't ideal candidates for edge-to-edge repair. This funding is crucial for generating the robust evidence needed to bring it to clinic."
Michael T. Ridgeway, Healthcare Portfolio Manager: "The oversubscribed round signals strong investor belief in both the technology and the addressable market. Mitral regurgitation remains a massively undertreated condition, and payers are increasingly open to solutions that reduce long-term heart failure costs. Polares is well-positioned."
Dr. Leo Crawford, Cardiac Surgeon (Retired): "Let's temper the hype. We've seen many 'revolutionary' catheters come and go. Replacing a delicate leaflet via catheter is an enormous engineering and biological challenge. Throwing $50 million at the problem doesn't guarantee success. I'll remain skeptical until I see five-year durability data."
Sarah Chen, Patient Advocate, Heart Valve Voice: "As someone who watched a parent go through open-heart surgery for MR, news of less invasive options is always emotional. The focus on anatomical variety gives me hope that more people, including those deemed 'too high-risk,' might eventually have a viable treatment path. This can't move fast enough."
This report is based on information originally published by Medical Device Network.